Extract from Eucommia ulmoides Oliv. ameliorates arthritis via regulation of inflammation, synoviocyte proliferation and osteoclastogenesis in vitro and in vivo  by Wang, Jian-Ying et al.
Contents lists available at ScienceDirect
Journal of Ethnopharmacology
journal homepage: www.elsevier.com/locate/jep
Extract from Eucommia ulmoides Oliv. ameliorates arthritis via regulation
of inﬂammation, synoviocyte proliferation and osteoclastogenesis in vitro
and in vivo
Jian-Ying Wang, Ying Yuan, Xiao-Jun Chen, Sheng-Guang Fu, Lei Zhang, Yan-Long Hong,
Sheng-Fu You, Yong-Qing Yang⁎
Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, No. 1200 Cailun Road, Pudong District, Shanghai,
China
A R T I C L E I N F O
Keywords:
Immunomodulation
Inﬂammation
Arthritis
Eucommia ulmoides Oliv.
Collagen-induced arthritis rat model
Extract
A B S T R A C T
Ethnopharmacological relevance: Eucommia ulmoides Oliv., a valuable Chinese herb, has shown a variety of
health beneﬁts. Despite the widespread clinical use of this herb to treat rheumatoid arthritis (RA) in Traditional
Chinese Medicine (TCM), very few studies have described its anti-pathological eﬀects or mechanism in RA. The
present study investigated the mechanism of Eucommia ulmoides Oliv. in an experimental collagen-induced
arthritis (CIA) rat model.
Materials and methods: The eﬀects of four diﬀerent Eucommia ulmoides Oliv. extracts on the proliferation of
rheumatoid arthritis ﬁbroblast-like synoviocytes (RA-FLS) were screened in an MTT assay, and apoptotic eﬀects
were detected by ﬂow cytometry. Among the extracts, the 70% ethanol extract (EU70) presented the best
inhibition and was further investigated for its curative eﬀect in CIA rats. Foot swelling was detected, and the
arthritis index (AI) was scored. Pathological improvement was assessed by haematoxylin and eosin (H& E)
staining of joint tissues. The mechanistic eﬀects of EU70 were investigated as follows: anti-inﬂammatory eﬀects
in Th17-positive cells by ﬂow cytometry; serum levels of inﬂammatory cytokines by ELISA; TNFα and IL-1β
expression by immunohistochemistry (IHC); and anti-osteoclastogenesis by QPCR detection of RANKL and
OPG mRNA.
Results: Compared with vehicle treatment in CIA model rats, EU70 signiﬁcantly ameliorated foot swelling,
decreased AI in vivo and reduced inﬂammatory cell inﬁltration and synoviocyte proliferation. EU70 decreased
the number of Th17-positive cells in the spleen and the serum levels of cytokines, including IL-17, IL-1β and
TNFα, and upregulated the serum levels of IL-10; these results indicated the anti-inﬂammatory eﬀect of EU70.
Moreover, EU70 eﬀectively suppressed TNFα and IL-1β expression in the joint tissues and resulted in the
downregulation of RANKL mRNA and the upregulation of OPG mRNA. These results revealed the possible
preventive role of EU70 against bone destruction.
Conclusion: For the ﬁrst time, these mechanisms and pathological improvements support the clinical use of
Eucommia ulmoides Oliv. in treating RA. The ﬁndings indicated that the 70% ethanol extract of Eucommia
ulmoides Oliv. could relieve RA symptoms by (1) suppressing the proliferation of synoviocytes, (2) reducing the
number of Th17-positive cells and downregulating serum IL-17 expression, (3) increasing the anti-inﬂamma-
tory eﬀects of IL-10, (4) inhibiting the serum and tissue levels of key pro-inﬂammatory cytokines, TNFα and IL-
1β, and (5) reducing the degradation of cartilage and bone.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic, inﬂammatory, and systemic
autoimmune disease (Arend, 2001). The basic pathological changes in
RA include the proliferation of rheumatoid arthritis-ﬁbroblast-like
synoviocytes (RA-FLS), thickening of the lining layer, inﬂammatory
cell inﬁltration, pannus formation, and cartilage and bone damage,
which all result in irreversible joint deformity and loss of function
(Kinne et al., 2000; Martínez et al., 2007). The standard treatment for
RA is a combination (Nagai et al., 2012) of analgesics and non-steroidal
anti-inﬂammatory drugs (NSAIDs) in the early stage to prevent RA
progression. Unfortunately, the use of these agents is limited by
gastroenteropathy, a limited clinical remission rate, ease of suppressing
immunity, secondary tumour formation, infection, and organ damage.
Herbal medicines, the main source of natural medicines, have unique
advantages in the treatment of RA due to their wide variety of sources,
reduced side eﬀects, and multiple activities, levels and targets (Soeken
and Miller et al., 2003). The identiﬁcation of eﬀective ingredients for
RA treatment from natural medicines is a topic of great interest and a
focus of extensive research and development eﬀorts (Soeken and Miller
et al., 2003).
Eucommia ulmoides Oliv. is a Chinese herb with a medicinal
history dating back 2000 years. The medicine-food homology of
Eucommia ulmoides Oliv. has been established by the Ministry of
Health, P.R. China, and Eucommia ulmoides Oliv. has been applied in
the clinic, including as an RA treatment. A search of nationwide
databases, including CNKI, VIP and Wanfang, reveals more than 150
Chinese publications on the use of Eucommia ulmoides Oliv. in RA
treatment. Eucommia ulmoides Oliv. ranks twelfth among prescrip-
tions used to treat rheumatic diseases at Tongxiang First People’s
Hospital of China (Wang et al., 2011). A statistical analysis of ten years
of hospitalized cases at the First Aﬃliated Hospital of Guangzhou
University of Traditional Chinese Medicine also supports the common
use of Eucommia ulmoides Oliv. to treat RA (Huang, 2009). Recent
studies have also revealed the eﬀects and mechanism of Eucommia
ulmoides Oliv. in osteoarthritis (OA) (Chen et al., 2014; Lu et al.,
2013). An analysis of prescriptions for OA treatment in Taiwan in 2002
determined that Eucommia ulmoides Oliv. was the most commonly
used single Chinese herb (Chen et al., 2014). However, few interna-
tional reports have examined the mechanism of Eucommia ulmoides
Oliv. in RA.
Eucommia ulmoides Oliv. exhibits the following pharmacological
activities: blood pressure reduction, diuresis, immune regulation, anti-
aging, anti-tumour, antibacterial, anti-inﬂammatory, and analgesic
eﬀects (Lee and Weinblatt, 2001). The eﬀective components of
Eucommia ulmoides Oliv. include lignans, ﬂavonoids, iridoids, sterols,
phenylpropanoids, phenolics and other molecules, such as triterpenes,
that possess anti-inﬂammatory and immune regulatory activities. The
use of terpenes to treat RA is particularly notable (Feng et al., 2015; He
et al., 2014). Aucubin, an iridoid present in Eucommia ulmoides Oliv.,
exhibits anti-inﬂammatory eﬀects (Bermejo et al., 2000). Kim et al.
(2015) determined that Eucommia cortex inhibits the production of
tumour necrosis factor-α (TNFα), interleukin-6 (IL-6), cyclooxygenase-
2, prostaglandin E and nitric oxide (NO) in lipopolysaccharide (LPS)-
treated peritoneal macrophages. Therefore, the mechanism underlying
the eﬀectiveness of Eucommia ulmoides Oliv. against RA may involve
anti-inﬂammatory and immunoregulatory activities. However, relevant
studies have not been reported.
Though Eucommia ulmoides Oliv. is widely used clinically and
possesses multiple components involved in anti-inﬂammation and
immune regulation, few studies have identiﬁed the pharmacological
mechanism of this herb. The aim of this study is to use extracts of
Eucommia ulmoides Oliv. to detect its eﬀects in treating RA and to
explore its underlying molecular mechanism of action. The inhibitory
eﬀects of Eucommia ulmoides Oliv. extracts on the proliferation of
human synoviocytes were assessed using MTT assays and ﬂow cyto-
metry. A collagen II-induced arthritis (CIA) rat model was then
established to investigate the in vivo anti-inﬂammatory and immune
regulatory mechanisms of the pharmacological eﬀects of Eucommia
ulmoides Oliv. to provide experimental evidence for its clinical
application in RA.
2. Materials and methods
2.1. Plant material
The cortex of Eucommia ulmoides Oliv. was purchased from
Shanghai Kangqiao Chinese Medicine Tablet Co., Ltd., (Shanghai,
China) and identiﬁed as family Eucommiaceae by Professor Wu
Jinrong of the Shanghai University of Traditional Chinese Medicine.
A voucher specimen (Wang, 9523) has been deposited in the
Department of Chinese Materia Medica, Shanghai University of
Traditional Chinese Medicine.
2.2. Extraction
The cortex of Eucommia ulmoides Oliv. (1 kg) was washed, sliced,
dried and then extracted twice with 70% ethanol or 90% ethanol (1:8
and 1:6, w-v, 3 days each time). Then, the extract was evaporated to a
small volume (1 g/mL) in vacuo to yield a 70% ethanol extract (EU70)
and a 90% ethanol extract (EU90). The water extract (EUw), and
ethanol precipitate from the EUw (EUwp) were purchased from
Yuanmu Biotech Co., Ltd (Shanghai, China).
2.3. Cell growth inhibition using the MTT assay
Human RA ﬁbroblast-like synoviocytes (RA-FLS) from patients
were purchased from Shanghai Rochen Pharma Co., Ltd., (Shanghai,
China) and cultured in 1640 medium with 10% foetal bovine serum
and 1% antibiotics in an atmosphere of 5% CO2 at 37 °C. RA-FLS at the
exponential (log) phase were seeded at a density of 2,000 cells/well/
200 μL in a 96-well plate. After overnight incubation, various doses of
EU70, EU90, EUw, EUwp and tripterygium glycosides (TG) were
added to the RA-FLS in triplicate. Medium was used as a blank. The
MTT method was used to assess inhibition after 24 h, 48 h, and 72 h of
growth at 37 °C. Brieﬂy, 20 μL of 5 mg/mL MTT in PBS was added to
each well. After 4 h of incubation, the OD at 490 nm was detected in
DMSO after the supernatant was removed. Inhibition ratio =(1-OD/
Blank OD)×100%.
2.4. Induction of CIA in rats and administration
In total, 32 female and 32 male Wistar rats (SLAC, Shanghai,
China) were housed under speciﬁc pathogen-free (SPF) conditions.
Animal welfare and experimental procedures were performed in
accordance with the institutional guidelines for the care and use of
laboratory animals and related ethical regulations of Shanghai
University of Traditional Chinese Medicine (2014028).
The method for generating the CIA rat model was modiﬁed from
Huang and Huang (2008). Brieﬂy, approximately 10 mg/mL bovine
type II collagen (CII) in 0.1 M acetic acid was emulsiﬁed with an equal
volume of complete Freund’s adjuvant (CFA) to create a stable CII/CFA
emulsion (5 mg/mL). With the exception of the control group (8 male
and 8 female rats), the rats were intradermally injected with the CII/
CFA emulsion in the tail (0.1 mL) and right hind paw (0.1 mL). At 7
and 21 days after the primary administration, each rat received 0.1 mL
of CII/CFA booster via intradermal injection in the tail.
On day 21, the CIA rats were randomly allocated to 3 groups
containing equal numbers of males and females. The CIA group, EU70
group and TG group were intragastrically infused with PBS, 2.7 g/kg of
EU70 or 5.4 mg/kg of TG once daily, respectively. The dose of EU70
was calculated from the dose for humans (China Pharmacopoeia
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Committee, 2015) based on equal body surface area (Xu, 2002).
2.5. Evaluation of arthritis
The body weights and right hind paw volumes of all rats were
monitored weekly. The right hind paw volumes were noted on a Digital
Plethysmometer (Shandong Academy of Medical Sciences, Shandong,
China). On days 7, 21, 35 and 49, the severity of arthritis was
semiquantitatively scored from 0 to 4: 0, normal; 1, mild swelling
conﬁned to the ankle joint and mid-tarsals; 2, moderate swelling
extending from the ankle to the metatarsal joints; 3, severe swelling
encompassing the ankle, foot and digits; and 4, severe swelling causing
joint swelling deformity and diﬃculty in walking (Leavenworth et al.,
2013).
2.6. Sample collection
On the 35th and 49th days, eight rats (four male and four female) in
each group were euthanized. Part of the hind limb joints from the rats
were ﬁxed in 10% formaldehyde for the subsequent experiments,
whereas the other part was preserved in liquid nitrogen. Blood was
obtained from the abdominal aorta, centrifuged at 4 °C to collect the
serum, and stored at −80 °C. Single splenocytes suspensions were
collected in an aseptic manner. Brieﬂy, the spleens were dissected and
added to PBS. The dissociated tissue was passed through a 200-mesh
cell strainer with grinding using a syringe to obtain the cell suspension.
After centrifugation, the cell pellet was suspended in ELS (erythrocyte
lysis solution) for several minutes to remove red blood cells. After
washing with PBS and centrifugation, single cells were cultured in
RPMI 1640 medium containing 10% FBS.
2.7. Flow cytometry
To measure cell apoptosis, RA-FLS were cultured at a density of
5×105 cells/well in a 6-well plate and treated with EU70 and EU90 for
48 h. The cells were harvested, washed and incubated with Annexin V-
FLUOS solution for 20 min in the dark, followed by incubation with PI
(50 μg/mL) for 10 min. Apoptotic cells were then detected with a
FACSCalibur (Becton Dickinson, New Jersey, USA) equipped with
EXPO32 V1.2 analysis software.
IL17-positive splenocytes were detected by incubating the cells with
IL-17A-FITC (eBioscience, California, USA) at room temperature for
30 min.
2.8. Enzyme-linked immunosorbent assay (ELISA)
Serum IL-10, IL-17, IL-1β and TNFα levels after treatment with
EU70 were determined using ELISA kits (eBioscience, California, USA)
according to the manufacturer's instructions.
2.9. Haematoxylin and eosin (H& E) staining and pathological
evaluation
Right posterior knee joints were ﬁxed in 10% formaldehyde,
dehydrated in an ethanol gradient series, embedded in paraﬃn, serially
sectioned into 5 µm slices, and stained. Changes in joint and synovial
tissues were observed and evaluated pathologically on a scale from 0 to
5: 0, normal; 1, inﬁltration with a few inﬂammatory cells or mild
oedema; 2, mild inﬁltration; 3, moderate inﬁltration; 4, obvious
inﬁltration; and 5, severe inﬁltration (LaBranche et al., 2010).
2.10. Immunohistochemistry (IHC) for TNFα and IL-1β
Following deparaﬃnization, antigen retrieval was performed by
heating the slices in citrate buﬀer, followed by treatment with 0.3%
hydrogen peroxide to block endogenous peroxidase activity and
incubation with goat serum to block non-speciﬁc binding. The slices
were incubated with primary antibodies against TNF-α and IL-1β
(Santa Cruz Biotechnology, California, USA) overnight at 4 °C. The
following day, the slices were washed and incubated with a secondary
antibody solution for 2 h at 37 °C. After washing, the slides were
developed with DAB (3,3′-diaminobenzidine), the nucleus was coun-
terstained with haematoxylin, and the slices were incubated with
xylene (to render them transparent) and mounted. The slides were
analysed using the IMS cell image analysis system, and the average
optical density was calculated as the Positive area percentage (%)×op-
tical density (OD).
2.11. Detection of RANKL and OPG mRNA levels by qRT-PCR
Fifty milligrams of joint tissue were ground in liquid nitrogen.
Then, RNA was extracted with TRIzol and reverse transcribed into
cDNA using an RT-PCR kit (TaKaRa, Japan). qRT-PCR was performed
using β-actin as a reference and SYBR green as the ﬂuorescent dye with
the following ampliﬁcation conditions: pre-denaturation at 95 °C for
30 s, 40 cycles of denaturation at 95 °C for 3 s, and annealing and
extension at 60 °C for 30 s. The primers were as follows: OPG-F,
tgggaatgaagatcctccag; OPG-R, cctctttctcagggtgcttg; RANKL-F, accag-
catcaaaatcccaag; RANKL-R, ggacgctaatttcctcacca; β-actin-F, agccatg-
tacgtagccatcc; and β-actin-R, accctcatagatgggcacag.
2.12. Statistical analysis
All statistical analyses were performed with the SPSS19.0 software
package (SPSS Inc., Chicago, IL, USA). Student's t-test was used for
comparisons between independent groups. A P value of less than 0.05
indicated a statistically signiﬁcant diﬀerence.
3. Results
3.1. The ethanol extract of Eucommia ulmoides Oliv. inhibits RA-FLS
proliferation
The MTT assay of cell viability was performed to screen for the
inhibitory eﬀects of several extracts of Eucommia ulmoides Oliv. on
RA-FLS. As shown in Fig. 1A, EU70, EU90 and TG inhibited RA-FLS
proliferation in a dose- and time-dependent manner. Treatment with
1,000 μg/mL EU70 at 48 h and 72 h, 1000 μg/mL EU90 at 72 h, and
most doses of TG resulted in greater than 50% inhibition and
signiﬁcant diﬀerences compared to the blank wells (P < 0.001),
whereas 1000 μg/mL EU70 exhibited a greater anti-proliferation eﬀect
than EU90 at both 48 h (63% vs. 23%, respectively) and 72 h (76% vs.
65%, respectively). Therefore, the ethanol extracts were screened in the
subsequent assay.
3.2. EU70 induces apoptosis and necrosis of RA-FLS
Apoptotic and necrotic cells were distinguished by ﬂow cytometry
with AnnexinV/PI detection. After 48 h of treatment (Fig. 1B), both
EU70 and EU90 increased cell apoptosis compared with the PBS group
(P < 0.001). Furthermore, EU70 promoted apoptosis to a greater extent
than EU90. Therefore, EU70 was selected as the representative extract
in the subsequent pathological and mechanistic assays in vivo.
3.3. EU70 ameliorates foot swelling and decreased the arthritis index
(AI)
As shown in Fig. 2A, no signiﬁcant weight loss was observed
between the EU70 group and model group, although the CII/CFA
emulsion induced arthritis and reduced weight compared with the
control group. These results suggest that EU70 does not have obvious
toxicity.
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Swelling increased obviously in the model compared with that of
the control group, leading to joint deformity and diﬃculty walking,
which were manifested as signiﬁcant increases in foot volume and AI
(P < 0.05). These results conﬁrmed that the CIA rat model was
developed successfully.
Compared to the CIA group, EU70 signiﬁcantly decreased joint
swelling, as indicated by reduction of both foot volume and AI, after 1
week of treatment. The maximum eﬀect was attained in the second
week (from days 35).
3.4. EU70 improves the pathology of the synovial membrane
As shown in Fig. 2B, the joint tissues of the control group were clear
and smooth, without hyperplasia and inﬂammatory cell inﬁltration.
After 35 days, the CIA group exhibited obvious hyperplasia of the
synovial tissue, aggressive structural disorder in the articular cavity,
inﬂammatory cell inﬁltration, and osteoclasts. Both the EU70 and TG
group rats exhibited synovial tissue hyperplasia and signiﬁcantly
reduced inﬁltration of inﬂammatory cells, whereas bone tissue destruc-
tion was observed in the TG group. After 49 days, the CIA rat model
exhibited serious synovial hyperplasia, inﬂammatory cell inﬁltration,
and bone tissue destruction with empty cavities. However, the TG
group of rats exhibited a lack of inﬂammation. The EU70 rats exhibited
a signiﬁcant decrease in inﬂammatory cell inﬁltration accompanied by
synovial tissue adhesion. There were signiﬁcant diﬀerences in the
pathological scores of the CIA model and drug groups, but not between
the EU70 and TG groups.
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Fig. 1. Of the various extracts of Eucommia ulmoides Oliv., EU70 exhibited the greatest inhibitory and apoptotic eﬀects against RA-FLS. A. MTT assay of RA-FLS cells treated with
various doses of TG, EU70, EU90, EUw, and EUwp for 24 h, 48 h and 72 h. B. Apoptosis assay of RA-FLS treated with EU70 and EU90 for 48 h. TG and PBS were used as positive and
negative controls, respectively.
J.-Y. Wang et al. Journal of Ethnopharmacology 194 (2016) 609–616
612
Fig. 2. EU70 alleviates the symptoms of RA in vivo and improves the pathological state of inﬂammation. A. Equal numbers of male and female rats were used to develop the CIA model
with a ﬁrst and booster immunization. After the ﬁrst subcutaneous injection of the CII/CFA emulsion (5 mg/mL) in the tail and right hind paw, the rats’ body weights, right hind paw
volume, and arthritis indexes were recorded on diﬀerent study days. B. Pathological sections of hind limb joints from normal (healthy), arthritic and drug-treated CIA rats (×40
magniﬁcation) were analysed by H&E staining. C. Inﬂammatory inﬁltration was assessed by scoring the H&E sections. #: P < 0.05 compared with the CIA group.
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Fig. 3. EU70 decreases pro-inﬂammatory cytokine levels and the number of T cells (Th17-positive cells) and increases anti-inﬂammatory cytokine levels (IL-10). (A) IHC of TNFα and
IL-1β in rat hind limb joints on day 49 (after 4 weeks of drug treatment) (×40). (B). Average optical density of IHC sections from the four groups. (C) Splenocytes were isolated from the
rats on day 35 and day 49. Th17-positive cells were stained with a FITC-conjugated Th17 antibody and detected by ﬂow cytometry. (D) Serum IL-10, IL-17, IL-1β and TNFα levels were
detected by ELISA. The rats were treated with the diﬀerent drugs on day 35 and day 49 after model generation. *: P < 0.05 compared with the normal group; #: P < 0.05 compared with
the CIA group.
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3.5. EU70 decreases the average optical density of TNFα and IL-1β
staining
On day 49, the intensity of TNFα-and IL-1β-positive immunohis-
tochemical staining in the model group was signiﬁcantly increased
compared with that of the control group (P < 0.001) (Fig. 3A and B),
whereas the EU70 group exhibited a signiﬁcant reduction in staining
intensity compared with the CIA group (P < 0.001) (Fig. 3B).
3.6. EU70 decreases the number of Th17-positive lymphocytes in the
rat spleen
On day 35, the percentage of Th17-positive cells in the spleen of the
EU70-treated rats (58.69 ± 8.31%) exhibited a decreasing trend com-
pared with the CIA control group (65.38 ± 6.20%). On day 49, the
EU70 intervention (7.43 ± 2.98%) signiﬁcantly reduced the number of
Th17-positive cells compared with the model group (13.44 ± 4.54%).
3.7. EU70 induces anti-inﬂammatory cytokine production and
reduces pro-inﬂammatory cytokines production
In the CIA model group, the serum levels of anti-inﬂammatory
cytokine and pro-inﬂammatory cytokines (IL-17, IL-1β and TNFα)
were signiﬁcantly decreased and increased, respectively, compared
with the control group. EU70 prevented the CIA-induced changes in
IL-10 and IL-17 levels at two weeks after administration and sig-
niﬁcantly reversed the change in cytokine levels at four weeks after
administration. Moreover, EU70 decreased the upregulation of IL-1β
and TNFα both at 2 weeks and four weeks.
3.8. EU70 alleviates bone destruction by increasing OPG and RANKL
mRNA levels
On day 35, the OPG and RANKL mRNA levels were signiﬁcantly
diﬀerent in the CIA group compared with the levels in the control
group, and EU70 signiﬁcantly alleviated the changes induced by CIA.
These improvements and the statistically signiﬁcant diﬀerences per-
sisted until day 49 compared with the CIA group (Fig. 4).
4. Discussion
The pathogenesis of RA involves multiple factors with complex
interactions (Qian and Zhao, 2013). The main target of attack is the
synovial joint, with increased inﬂammation leading to bone and
cartilage destruction. Therefore, synoviocyte apoptosis and anti-in-
ﬂammation are important targets of RA treatment (Baier et al., 2003).
Eucommia ulmoides Oliv. is a historical and valuable Traditional
Chinese Medicine (TCM). The immune enhancement, anti-osteoporo-
sis, anti-inﬂammation and antibacterial eﬀects of Eucommia ulmoides
Oliv. have been recently identiﬁed (Wang et al., 2013). However, there
are few research articles describing the use of Eucommia ulmoides
Oliv. to treat RA. We obtained four Eucommia ulmoides Oliv. extracts
using diﬀerent solvent extraction methods and screened their corre-
sponding anti-proliferative activity in RA-FLS. EU70 exhibited the
strongest inhibition. The apoptosis assay indicated that EU70 eﬀec-
tively promoted RA-FLS apoptosis. Additionally, H & E staining of the
swelling joint revealed that EU70 inhibited the pathologic proliferation
of the synovial tissue. Based on these results, EU70 was used as the
agent in subsequent mechanistic assays.
For RA treatment in vivo, the pathological improvements of EU70-
reduced AI, foot swelling, and inﬂammatory cell inﬁltration reﬂect the
anti-inﬂammation mechanisms. Inﬂammation-related factors were
explored because inﬂammation is the main cause and symptom of
RA Th17-positive cells are a subset of T cells that produce IL-17 and
promote the occurrence and development of inﬂammation. The
upregulated production of IL-6, TNFα, IL-1 and other inﬂammatory
cytokines by Th17 cells and IL-7 can synergistically promote the
emergence and development of inﬂammation (Jovanovic et al., 1998;
Yamaguchi et al., 2007). Th17 cells can induce synoviocyte prolifera-
tion (Lee et al., 2013), upregulate RANKL expression (Kim et al.,
2015), increase osteoblast formation and lead to bone destruction
(Braun and Zwerina, 2011). Flow cytometry revealed that EU70
reduced the CIA-induced increase in the number of Th17-positive
lymphocytes and serum IL-17 levels, which may comprise part of the
anti-inﬂammatory mechanism. IL-10 is a multi-functional, negative
cytokine that acts to reduce the inﬂammatory response and the
expression of inﬂammatory mediators (Bazzoni et al., 2010). IL-10
reduces the migration of lymphocytes to lesions by inhibiting the
production of pro-inﬂammatory cytokines and increases the levels of
endogenous anti-inﬂammatory substances, such as soluble TNFα
receptor and IL-1 receptor antagonists, thereby suppressing TNFα
and IL-1 production to inhibit disease progression (St. Clair, 1999).
Our ELISA assay also demonstrated that EU70 increased serum IL-10
levels, further indicating the role for IL-10 in the anti-inﬂammatory
mechanism of EU70.
As shown by IHC and ELISA, CIA-induced TNFα and IL-1β
production in the joints and serum was signiﬁcantly decreased by
EU70, indicating a strong anti-inﬂammatory eﬀect. TNFα is the core
pro-inﬂammatory cytokine and plays an important role in immune
regulation. TNFα upregulation induces cartilage matrix degradation
and collagen decomposition, promotes platelet aggregation, and in-
duces inﬂammatory cell inﬁltration. TNFα-targeted antagonists have
been commercially developed and used in the clinic (Vinay and Kwon,
2012). Furthermore, as IL-1β may regulate numerous cytokines,
immune regulators and pro-inﬂammatory mediators, this cytokine
plays an important role in bone erosion and cartilage destruction in
RA (Lee and Weinblatt, 2001). The downregulation of TNFα and IL-1β
production by EU70 might by another anti-RA mechanism.
Bone destruction is the main cause of arthritis disability e regulated
by the immune system; notably, RANKL-OPG is the bridge between
bone and the immune system. RANKL is a member of the tumour
necrosis factor super family. Several clinical studies have found
Fig. 4. EU70 decreases RANKL mRNA levels and increases OPG mRNA levels in joint tissue. *: P < 0.05 compared with the control group; #: P < 0.05 compared with the CIA group.
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signiﬁcantly increased RANKL levels in RA joint ﬂuid, synovial tissue
and peripheral blood mononuclear cells proportional to the degree of
RA joint damage (Geusens, 2012; Miyazaki et al., 2007; Silva and
Branco, 2011; Takayanagi, 2010). OPG belongs to the TNF receptor
super family and is a decoy receptor of RANKL that can prevent the
binding of RANKL to its receptor, thus inhibiting the intensiﬁcation of
osteoclast diﬀerentiation (Romas et al., 2002). The expression of
RANKL in activated T lymphocytes may provide a link between the
immune system and bone metabolism in RA. EU70 induced the
upregulation of OPG mRNA and the downregulation of RANKL
mRNA in synovial tissue, indicating resistance to the CIA-induced
bone destruction.
In combination with the results of previous reports about RA
cytokines, these results of this study indicate that improvements in
the immune system may relieve the sensitization to RA pathology,
adjust the dynamic balance of the bone tissue, and alleviate the
destruction of bone tissue by CIA.
Compared with the CIA model group, body weight did not decrease
signiﬁcantly in the EU70 groups, suggesting that EU70 had no obvious
toxicity.
This study is the ﬁrst to show the eﬀects and mechanism of
Eucommia ulmoides Oliv on RA. EU70 acts on multiple targets of
RA treatment. The possible mechanisms may include (1) inhibiting
synoviocyte proliferation; (2) inhibiting Th17 cells in vivo; (3) increas-
ing the downregulatory eﬀect of IL-10 on inﬂammation; (4) inhibiting
the expression of the pro-inﬂammatory cytokines IL-1β and TNFα in
joint tissue and serum; and (5) upregulating the expression of the
RANKL decoy receptor OPG and downregulating RANKL expression,
which prevents bone tissue damage. Therefore, further research on
Eucommia ulmoides Oliv. is warranted.
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